Agilent Technologies, Inc. (NYSE:A) Shares Bought by Oak Thistle LLC

Oak Thistle LLC raised its position in Agilent Technologies, Inc. (NYSE:AFree Report) by 8.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,121 shares of the medical research company’s stock after acquiring an additional 314 shares during the quarter. Oak Thistle LLC’s holdings in Agilent Technologies were worth $573,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Agilent Technologies during the fourth quarter worth about $393,291,000. Victory Capital Management Inc. grew its position in shares of Agilent Technologies by 939.8% during the third quarter. Victory Capital Management Inc. now owns 2,296,512 shares of the medical research company’s stock worth $256,796,000 after buying an additional 2,075,649 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Agilent Technologies by 233.7% during the fourth quarter. Nordea Investment Management AB now owns 2,666,416 shares of the medical research company’s stock worth $370,552,000 after buying an additional 1,867,377 shares in the last quarter. Morgan Stanley grew its position in shares of Agilent Technologies by 79.4% during the fourth quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock worth $620,414,000 after buying an additional 1,835,413 shares in the last quarter. Finally, Meritage Group LP acquired a new position in shares of Agilent Technologies during the third quarter worth about $184,437,000.

Insider Activity

In other news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total value of $7,844,550.00. Following the transaction, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Rodney Gonsalves sold 4,828 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the transaction, the vice president now directly owns 21,329 shares in the company, valued at approximately $3,178,021. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Analyst Ratings Changes

A has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price objective on Agilent Technologies from $128.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 7th. Wolfe Research assumed coverage on Agilent Technologies in a research note on Wednesday, December 13th. They set an “outperform” rating and a $140.00 target price for the company. UBS Group boosted their target price on Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Oppenheimer boosted their target price on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Finally, Citigroup boosted their target price on Agilent Technologies from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $138.29.

View Our Latest Report on Agilent Technologies

Agilent Technologies Price Performance

Shares of NYSE A opened at $143.73 on Thursday. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $151.58. The stock has a 50 day moving average of $139.08 and a two-hundred day moving average of $127.25. The stock has a market cap of $42.12 billion, a P/E ratio of 34.22, a P/E/G ratio of 4.41 and a beta of 1.11.

Agilent Technologies (NYSE:AGet Free Report) last released its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s revenue for the quarter was down 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.37 earnings per share. On average, research analysts forecast that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be issued a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s payout ratio is currently 22.38%.

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Further Reading

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.